ArticleScientific reports2026
Overall survival across registry-defined biopsy and registry-defined STR categories in glioblastoma: a population-based matched and weighted SEER study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
In glioblastoma (GBM), biopsy and subtotal resection are clinically distinct concepts, but registry datasets may not distinguish them with sufficient neurosurgical precision. We therefore evaluated whether SEER registry-defined biopsy and registry-defined STR categories were associated with overall survival (OS), while explicitly recognizing that these codes do not capture radiographic residual tumor volume, operative intent, or validated extent-of-resection definitions. Using Surveillance, Epidemiology, and End Results (SEER) data (2004–2019), GBM cases were identified (ICD-O-3: 9440, 9441, 9442). Surgery was defined by SEER code 20 (biopsy) and code 21 (registry-defined STR). The primary analysis excluded patients with survival of ≤ 1 month; sensitivity analyses included them. Propensity score matching (PSM) and stabilized inverse probability of treatment weighting (sIPTW) were used to reduce measured baseline imbalance. Survival was assessed with Kaplan–Meier analysis and Cox proportional hazards models. Of 10,359 patients, 4,774 were coded as biopsy and 5,585 as registry-defined STR. In the unadjusted cohort, registry-defined STR was associated with better OS in univariable analysis (HR 0.951, 95% CI 0.912–0.991; P = 0.017), but this association was not significant after multivariable adjustment (HR 1.010, 95% CI 0.968–1.054; P = 0.645). Similar non-significant findings were observed in the PSM cohort (HR 1.029, 95% CI 0.978–1.083; P = 0.268) and the sIPTW-weighted cohort (HR 1.008, 95% CI 0.962–1.056; P = 0.726). Sensitivity analyses yielded consistent results. Within SEER registry-coded surgical categories, registry-defined STR was not associated with an adjusted OS difference versus biopsy in patients with GBM. However, because SEER cannot reliably distinguish these procedures as clinically validated surgical entities, the findings should be interpreted primarily as a registry-coding analysis with limited surgical interpretability, rather than as evidence that biopsy and registry-defined STR are equivalent strategies in practice. Future studies with postoperative imaging-based extent-of-resection measures and richer clinical, molecular, radiographic, and functional data are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.